Clinical criteria updates

On November 19, 2021, December 13, 2021, and January 10, 2022, the Pharmacy and Therapeutics (P&T) Committee approved the following Clinical Criteria applicable to the medical drug benefit for Anthem Blue Cross. These policies were developed, revised, or reviewed to support clinical coding edits.

 

Visit Clinical Criteria to search for specific policies. For questions or additional information, use this email.

 

Please see the explanation/definition for each category of Clinical Criteria below:

• New: newly published criteria
• Revised: addition or removal of medical necessity requirements, new document number
• Updates marked with an asterisk (*) notate that the criteria may be perceived as more restrictive

 

Please share this notice with other members of your practice and office staff.

 

Please note: The Clinical Criteria listed below applies only to the medical drug benefits contained within the member’s medical policy. This does not apply to pharmacy services.

 

Effective date	Document number	Clinical Criteria title	New or revised
June 7, 2022	*ING-CC-0205	Fyarro (sirolimus albumin bound)	New
June 7, 2022	*ING-CC-0206	Besremi (ropeginterferon alfa-2b-njft)	New
June 7, 2022	*ING-CC-0207	Vyvgart (efgartigimod alfa-fcab)	New
June 7, 2022	*ING-CC-0208	Adbry (tralokinumab)	New
June 7, 2022	*ING-CC-0209	Leqvio (inclisiran)	New
June 7, 2022	ING-CC-0124	Keytruda (pembrolizumab)	Revised
June 7, 2022	ING-CC-0079	Strensiq (Asfotase Alfa)	Revised
June 7, 2022	ING-CC-0102	Gonadotropin releasing hormone (GNRH)  Analogs for Oncologic Indications	Revised
June 7, 2022	ING-CC-0168	Tecartus (brexucabtagene autoleucel)	Revised
June 7, 2022	ING-CC-0029	Dupixent (dupilumab)	Revised
June 7, 2022	*ING-CC-0004	Repository Corticotropin Injection	Revised
June 7, 2022	ING-CC-0072	Selective Vascular Endothelial Growth Factor (VEGF) Antagonists	Revised

Email is the quickest and most direct way to receive important information from Anthem Blue Cross.

To start receiving email from us (including some sent in lieu of fax or mail), submit your
information using the QR code to the right or via our online form (https://bit.ly/3lLgko8).

ACA-NU-0420-22